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Abstract: Epidemiological studies indicate that overweight and
obesity are associated with increased cancer risk. To study how obes-
ity augments cancer risk and development, we focused on hepatocel-
lular carcinoma (HCC), the common form of liver cancer whose
occurrence and progression are the most strongly affected by obesity
among all cancers. We now demonstrate that either dietary or
genetic obesity is a potent bona ﬁde liver tumor promoter in mice.
Obesity-promoted HCC development was dependent on enhanced
production of the tumor-promoting cytokines IL-6 and TNF, which
cause hepatic inﬂammation and activation of the oncogenic tran-
scription factor STAT3. The chronic inﬂammatory response caused
by obesity and enhanced production of IL-6 and TNF may also
increase the risk of other cancers.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.In developed countries, obesity and overweight pose major
health problems because of chronic diseases and the increased
mortality rate related to these conditions. Among the obesity
related diseases, cancer has a particular position. In 2003, in a
large prospective study, Calle and collaborators found that
increased body-mass index (BMI) was signiﬁcantly associated
with increased death rates for all cancers combined. In this study,
liver tumors showed the highest increase of risk in men with BMI
P35 (RR = 4.52 CI 95% [2.94–6.94]), whereas in women this
excess of risk was lower (RR = 1.68, CI 95% [0.93–3.05]) [1]. Based
on clinical and biological associations, several explanations have
been proposed to elucidate how obesity could promote the devel-Journal of Hepatology 20
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tis (NASH) that is clearly identiﬁed as a risk factor for HCC sug-
gesting that insulin resistance and inﬂammation could promote
tumor development. Moreover, as a paradigm, chronic inﬂamma-
tion has been associated with tumor promotion in various dis-
eases and a link between inﬂammation and tumor development
has been clearly demonstrated [2]. In this line, the team of
Michael Karin has previously shown that interleukin 6 (IL-6), a
pro-inﬂammatory cytokine produced by Kupffer cells, partici-
pates in hepatocarcinogenesis in mouse [3]. They also showed
that in females, estrogens inhibit IL-6 production, a possible clue
for the enigma of gender difference in HCC occurrence found in
epidemiologic data. However, until recently, experimental data
analyzing and dissecting the functional consequences of obesity
and non-alcoholic fatty liver disease (NAFLD) in inﬂammation
and HCC formation were lacking.
In a study published in January in Cell, Michael Karin’s team
addressed this issue using an elegant strategy [4]. They studied
the development of HCC chemically induced by diethylnitros-
amine (DEN) in C57/BL6 mice with normal or high fat diet result-
ing in dietary obesity. HCC was also induced by DEN in a leptin
deﬁcient mouse, a classical model for genetic obesity. In this
experiment, the authors showed that dietary and genetic obesity
strongly enhance the development of HCC with an increased
number and size of the tumors when compared to DEN mice on
normal chow. Tumors developed in obese mice demonstrated
an increased cell proliferation and a decrease in apoptosis, even
if HCC were transplanted in lean mice. Obese mice showed an
enhanced expression and a high serum level of inﬂammatory
cytokines, especially IL-6 and TNFa (tumor necrosis factor alpha).
Theses two cytokines were responsible, in non-tumor and tumor
tissues, of the activation of STAT3 by phosphorylation. STAT3 is
an oncogenic transcription factor known to be activated in sev-
eral tumor types in humans and it is the major transcription fac-
tor responsible for the acute inﬂammatory response in
hepatocytes. To demonstrate the key role of IL-6 and TNFa in
the increased development of HCC, the authors injected DEN in
obese mice genetically inactivated for IL-6 or for the TNF receptor
1 (TNFR1). In KO mice, the promotion of obesity-increased rate of
HCC was suppressed. The absence of IL-6 or TNFR1 also pre-
vented the obesity-induced increase in JNK, ERK, and STAT3
phosphorylation. Moreover, obese mice KO for IL-6 and TNF recep-
tor have a lower amount of lipid in the liver and also less inﬂam-10 vol. 53 j 777–779
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matory inﬁltrates than obese wild type mice. From these results,
we can conclude that IL-6 and TNFa are key factors in activating
cell proliferation and in increasing tumorigenesis through STAT3
phosphorylation in obese mice. Moreover, IL-6 and TNFa are also
necessary in obese mice for the development of steatosis and ste-
atohepatitis typically found in humans NAFLD (Fig. 1).Fig. 1. Implication of IL-6 and TNFa pathway in obesity related hepatocarcinogenes
factor a; IL-6R, IL-6 receptor; JAK ½, janus kinase 1 and 2; gp130, glucoprotein 130; STA
element; TNFR1/2, TNF receptor 1 and 2 ; TRADD, tumor necrosis factor receptor type 1-a
mitogen-activated protein kinase; NF-kappab, nuclear factor Kb; DEN, diethylnitrosamin
778 Journal of Hepatology 201One of the important results of this paper is the link demon-
strated between the etiology of chronic liver disease (NAFLD)
and a particular mechanism of tumor promotion through pro-
inﬂammatory cytokine signaling. It also underscores the role of
the IL-6/JAK/STAT signaling pathway that will provide insights
into our understanding of hepatocarcinogenesis. STAT3 is consid-is. NASH, non-alcoholic steatohepatitis; IL-6, interleukin 6; TNFa, tumor necrosis
T3, signal transducer and activator of transcription 3; APRE, acute phase response
ssociated DEATH domain protein; TRAF2, TNF receptor-associated factor 2; MAPK,
e; OH, alcohol; HCC, hepatocellular carcinoma; M/, macrophage.
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ered as an oncogene in a mouse model of activating mutation [5]
but also it has been found activated, through its phosphorylation,
in many types of human cancer including HCC [6]. Interestingly,
the group of Michael Karin has recently shown in a mouse model
that IKKb/NF-kappab prevents ROS accumulation, STAT3 related
activation, and tumor progression [7]. Underlining the impor-
tance of the IL-6 pathway in tumorigenesis, we also identiﬁed
recurrent somatic mutations activating gp130, the transducer of
signals for IL-6, in 60% of the benign hepatocellular adenomas
with inﬂammatory phenotype and also in a small subset of HCC
[8]. These observations suggest that IL-6 activation could be an
early event in hepatocellular tumorigenesis both in mice and
humans. This could have a very promising therapeutic implica-
tion since the IL-6/JAK/STAT pathway could be specially targeted,
for example by a JAK inhibitor developed initially against hema-
topoietic malignancy. As demonstrated in the present study,
treatment with JAK inhibitor (AG490) is followed by a dramatic
reduction of tumor growth and STAT3 activation of the DEN-
induced HCC in obese mice. On the other hand, the authors
showed that obesity activates the mTOR pathway together with
AKT inactivation in the non-tumor liver tissues. This result sug-
gests that mTOR inhibitors could be more efﬁcient to prevent
the occurrence of HCC related to obesity than targeting AKT itself.
These important ﬁndings lead us to ask new questions. In the
obese mouse model, induction of liver tumors required DEN;
obesity and high levels of cytokine alone are not sufﬁcient. Car-
cinogen exposure is needed to promote tumorigenesis. In this
model, activation of the IL-6 and the TNFa pathways alone is
probably not sufﬁcient to induce HCC and the accumulation of
other somatic alterations induced by carcinogen exposure are
required. In the same way, in humans, gp130 activation is mainly
related to benign tumorigenesis and in malignant liver tumors,
gp130 is associated with additional ß-catenin activating muta-
tions, the oncogene the most frequently mutated in human
HCC. Thus, cooperation of IL-6/STAT3 with other carcinogenesis
pathways remains to be explored. Finally, in obese mice, adipo-
cytes, Kupffer cells, or hepatocytes can produce IL-6 and TNFa.
In the present model, as in human NAFLD, it remains importantJournal of Hepatology 201to precisely understand the ‘‘primo movens” of the pro-inﬂamma-
tory state according to its cellular origin and its role in
hepatocarcinogenesis.Conﬂict of interest
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